1928 Diagnostics
1928 Diagnostics is a Swedish cloud-bioinformatics company whose 1928 Platform converts raw microbial sequencing data into actionable results — including AMR profiling, outbreak tracing, and microbiome analysis — for hospitals, CROs, pharma, and academic labs worldwide.
- Company typePrivate
- Founded2014
- HeadquartersGothenburg, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What 1928 Diagnostics does
1928 Diagnostics is a Swedish cloud-bioinformatics company founded in 2014 that operates a single platform — the 1928 Platform — for converting raw microbial sequencing data into clinically actionable results. The platform ingests fastq files from all major sequencing providers (Illumina, Ion Torrent, Oxford Nanopore, PacBio, Element Biosciences, MGI) and runs automated pipelines for whole genome sequencing, cgMLST- and SNP-based outbreak tracing, 16S/ITS amplicon analysis, shotgun metagenomics, microbiome analysis, and custom projects. Proprietary cgMLST schemes covering more than 25 pathogen species and curated, frequently updated reference databases form the analytical core. The platform is positioned for users without bioinformatics expertise, and is delivered as ISO 27001-certified, HIPAA- and GDPR-compliant cloud infrastructure.
The company sells through a hybrid GTM: direct self-serve cloud subscription and credit-based usage, supplemented by enterprise field sales and regional channel partners (Sciencewerke in APAC, Dlongwood in Spain and Portugal, LionDx in Italy). It targets four primary verticals — healthcare professionals (hospitals and clinical microbiology labs), contract research organizations, pharma/biotech, and academia — with named references including Karolinska University Hospital and the MMPG Laboratory. Strategic partnerships with Genomic Medicine Sweden and Chalmers University anchor its domestic Swedish position, and a New York subsidiary handles the North American market. Products are labeled For Research Use Only.
1928 Diagnostics AB is privately held, headquartered at Stena Center in Gothenburg with a US office in New York. The company has raised approximately $9.5M across disclosed rounds from 2015 to 2024, with Chalmers Ventures AB and Sciety among the named backers, and operates with a small team (1–10 employees). Revenue, ownership structure, and headcount trajectory are not publicly disclosed.
1928 Diagnostics firmographics
Firmographics- Name
- 1928 Diagnostics
- Legal name
- 1928 Diagnostics AB
- Website
- https://1928diagnostics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- 1928 Diagnostics is a Swedish cloud-bioinformatics company whose 1928 Platform converts raw microbial sequencing data into actionable results — including AMR profiling, outbreak tracing, and microbiome analysis — for hospitals, CROs, pharma, and academic labs worldwide.
- Ownership category
- akta.pro rank
1928 Diagnostics industry classification
Industry- Product category
- Bioinformatics and genomic data analytics
- NAICS
- Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industry
- Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)
Keywords
Where 1928 Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Gothenburg
- HQ country
- Sweden
- HQ region
- Europe
Offices3 records
Markets served
1928 Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- Cloud Platform Subscription: Subscription-based access to the 1928 bioinformatics platform with automated data processing, analysis pipelines, and expert support. Users can activate accounts through purchase of subscription or credits. The platform processes raw sequencing data and delivers actionable results.
- Usage-based Credits: Pay-per-use model where users purchase credits to access platform capabilities. Instant activation of accounts through credit purchase, allowing flexibility for varying analysis needs.
- Custom Project Services: Tailored bioinformatics analysis services for custom research projects with specialized analyses meeting unique project requirements. Quote-based engagement for specialized services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Subscription-based platform access with automated analysis and expert support |
| Usage-based | Pay-as-you-go | Pay-per-use credit system for flexible access to platform capabilities |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
1928 Diagnostics product offering
Product offeringCore offering
1928 Diagnostics operates a cloud-based bioinformatics platform (the 1928 Platform) that ingests raw sequencing data (fastq files) from all major sequencing providers and delivers automated analysis results—microbial identification, strain typing, AMR profiling, outbreak tracing, 16S/ITS amplicon, shotgun metagenomics, and microbiome diversity—within minutes, without requiring users to operate in-house bioinformatics infrastructure. Access is sold via subscription and usage-based credits, supplemented by tailored custom-project services.
Product overview
1928 Diagnostics offers a unified cloud-based bioinformatics platform (the 1928 Platform) that provides a suite of analysis solutions. The core portfolio includes Whole Genome Sequencing (WGS) for pathogen characterization, Outbreak Tracing powered by cgMLST and SNP analysis, 16S/ITS Amplicon Analysis for microbial diversity profiling, Shotgun Metagenomics for comprehensive community analysis, and Microbiome Analysis with automated pipelines. Custom Projects add-on services provide tailored solutions for unique research requirements. All solutions are delivered as a cloud-based Software-as-a-Service platform requiring no local infrastructure or bioinformatics expertise.
Differentiator
Problem solved
Functional benefit
Products and services
- 1928 Platform Cloud-based bioinformatics platform that transforms raw sequencing data (fastq files) from all major sequencing providers into actionable analysis results within minutes, without requiring users to operate in-house bioinformatics infrastructure. Delivered as SaaS with subscription and usage-based credit activation.
- Whole Genome Sequencing (WGS) Analysis Automated WGS analysis of cultured isolates delivering microbial identification, strain typing, antibiotic resistance profiling, virulence factor identification, phylogenetic analysis, and metabolic pathway analysis. Used by hospital microbiology labs, public health, and research groups.
- Outbreak Tracing
Quantifiable outcome
- Results delivered in minutes instead of months
- +1 more outcomes
Companies that use 1928 Diagnostics
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
1928 Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability2 records
Feature11 records
1928 Diagnostics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Genomic Medicine SwedencorePartnership focused on translating genomics innovation into clinical practice and implementing sustainable infrastructure for precision medicine in Sweden. Accelerating the benefits of genomic medicine for patients and healthcare professionals through clinically actionable insights.
- Chalmers University of TechnologycorePartnership pushing for solutions to important societal challenges, testing new ideas, and contributing to development of a sustainable future. The company's headquarters at Stena Center is part of an innovation community with roots in Chalmers University of Technology.
- SciencewerkecoreRegional distribution partner delivering 1928 Diagnostics services to the life science, research, and biotechnology sectors throughout Australia and the Asia-Pacific region.
- DlongwoodcoreRegional distribution partner delivering 1928 Diagnostics services to microbiology labs in Spain and Portugal.
- LionDxcoreRegional distribution partner delivering 1928 Diagnostics services to microbiology labs in Italy.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
1928 Diagnostics competitors and assessment
Company assessmentDirect peers
- CosmosID: CosmosID provides a commercial bioinformatics platform for microbial identification, AMR gene detection, and outbreak tracking using WGS and metagenomics data. Directly comparable to 1928 Diagnostics in target customers (clinical microbiology, food safety, pharma QC) and core product capabilities.
- One Codex: One Codex offers a cloud-based platform for microbial genomics analysis supporting WGS, metagenomics, and 16S workflows. Competes head-to-head with 1928 in serving clinical labs, public-health agencies, and food/agriculture customers with sequencing analysis.
- Velsera (formerly Seven Bridges Genomics): Velsera operates a cloud bioinformatics platform serving genomics labs, pharma, and clinical research with multi-omics analysis. Comparable in serving CRO and pharma customers with managed bioinformatics infrastructure at scale.
- Geneious (Biomatters): Geneious offers a commercial bioinformatics platform for sequence analysis including microbial genomics and metagenomics. Targets academic and applied research labs with desktop and cloud workflows that overlap with 1928's platform capabilities.
- IDbyDNA (now part of Illumina): IDbyDNA developed a metagenomics-based infectious disease detection platform that was acquired by Illumina. Its clinical metagenomics focus on pathogen ID and AMR from sequencing data overlapped directly with 1928's WGS and shotgun metagenomics offerings.
Broad incumbents
- QIAGEN CLC Genomics Workbench: QIAGEN's CLC bioinformatics suite is an established genomics analysis platform used across pharma, academia, and clinical research. Overlaps with 1928 in NGS-based microbial analysis but is part of a much broader life-science tools portfolio rather than a sequencing-specialist.
- Illumina (BaseSpace Sequence Hub): Illumina's BaseSpace Sequence Hub provides cloud-based tertiary analysis tightly integrated with Illumina sequencers. As the dominant sequencer vendor, Illumina's bundled analysis tools represent the most direct platform-level competitive threat to 1928.
- DNAnexus: DNAnexus provides a regulated cloud bioinformatics platform serving clinical diagnostics, pharma R&D, and large-scale genomics initiatives. Comparable in cloud-native architecture and serving healthcare/pharma customers, though broader in scope than 1928's pathogen-genomics focus.
- Oxford Nanopore (EPI2ME): Oxford Nanopore's EPI2ME platform provides cloud-based analysis workflows tightly bundled with Nanopore sequencers. While 1928 supports Nanopore data, EPI2ME is a vendor-controlled competing workflow that could limit 1928's penetration into Nanopore-heavy labs.
Emerging players
- BugSeq: BugSeq provides a free, open-source bioinformatics platform for clinical metagenomics and pathogen detection. While smaller and more narrowly focused than 1928, it addresses overlapping clinical microbiology use cases and represents a free alternative for budget-constrained labs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
1928 Diagnostics social profiles
Digital presence1928 Diagnostics compliance and trust
Trust signalCompliance3 records
1928 Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
1928 Diagnostics leadership team
Management profileNumber of profiles
Profiles5 records
1928 Diagnostics subsidiaries and ownership
Company hierarchySubsidiaries1 record
1928 Diagnostics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
1928 Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 1928 Diagnostics
What does 1928 Diagnostics do?
1928 Diagnostics operates a cloud-based bioinformatics platform (the 1928 Platform) that ingests raw sequencing data (fastq files) from all major sequencing providers and delivers automated analysis results—microbial identification, strain typing, AMR profiling, outbreak tracing, 16S/ITS amplicon, shotgun metagenomics, and microbiome diversity—within minutes, without requiring users to operate in-house bioinformatics infrastructure. Access is sold via subscription and usage-based credits, supplemented by tailored custom-project services.
Is 1928 Diagnostics a public or private company?
1928 Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was 1928 Diagnostics founded?
1928 Diagnostics was founded in 2014. It employs 1 to 10 people.
Where is 1928 Diagnostics based?
1928 Diagnostics is headquartered in Gothenburg, Sweden, in the Europe region.
How does 1928 Diagnostics make money?
Three revenue lines are on record. Cloud Platform Subscription is the primary driver. The others are usage-based Credits and custom Project Services.
Who are 1928 Diagnostics's main competitors?
Direct peers on record are CosmosID, One Codex, Velsera (formerly Seven Bridges Genomics), Geneious (Biomatters) and IDbyDNA (now part of Illumina). Broad incumbents are QIAGEN CLC Genomics Workbench, Illumina (BaseSpace Sequence Hub), DNAnexus and Oxford Nanopore (EPI2ME). BugSeq is listed as an emerging player.
Does 1928 Diagnostics have an API?
No public API is recorded for 1928 Diagnostics.
What industry is 1928 Diagnostics in?
1928 Diagnostics's product category is Bioinformatics and genomic data analytics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 518 and its SIC code is 7372.